Expression and use of anti-CD20 Antibodies
View Patent ↗Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.
1. A method of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active chimeric anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host, wherein the antibody comprises a light chain variable region comprising amino acid residues 23 to 128 of SEQ ID NO: 4, a human immunoglobulin light chain kappa constant region, a heavy chain variable region comprising amino acid residues 20 to 140 of SEQ ID NO: 6, and a human immunoglobulin heavy chain gamma 1 constant region.
2. The method of claim 1 wherein the antibody is administered to the host in four separate infusions of 375 mg/m 2 per infusion.
3. The method of claim 1 wherein the administration of the antibody causes peripheral blood B cells in the host to be depleted for a period in excess of 2 weeks.
4. A method for depleting peripheral blood B cells in a host in need of such treatment comprising administering an amount of an immunologically active chimeric anti-CD20 sufficient to induce B cell depletion, wherein the antibody comprises a light chain variable region comprising the amino acid sequence shown as residues 23 to 128 of SEQ ID NO: 4 and a heavy chain variable region comprising the amino acid sequence shown as residues 20 to 140 of SEQ ID NO: 6, and the amount of antibody administered comprises four separate infusions of 375 mg/m 2 .
5. A method of depleting peripheral blood B cells in a host in need of such treatment comprising administering an amount of an immunologically active chimeric anti-CD20 antibody sufficient to induce B cell depletion, wherein the antibody is the product of a host cell comprising nucleic acid sequences encoding the light chain and heavy chain of the antibody, wherein the sequence encoding the light chain comprises a nucleotide sequence encoding amino acid residues 23 to 128 of SEQ ID NO: 4 and the sequence encoding the heavy chain comprises a nucleotide sequence encoding amino acid residues 20 to 140 of SEQ ID NO: 6; and wherein the host cell is capable of expressing and secreting the antibody.
6. The method of claim 5 , wherein the nucleic acid sequence encoding the light chain further comprises a sequence encoding a human immunoglobulin constant region and the nucleic acid sequence encoding the heavy chain further comprises a sequence encoding a human immunoglobulin gamma 1 constant region.
7. The method of claim 5 , wherein the amount of antibody administered comprises four separate infusions of 375 mg/m 2 .
8. A method for depleting peripheral blood B cells in a host in need of such treatment comprising administering to the host an immunologically active chimeric anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host for a period in excess of 2 weeks following the administration, wherein the antibody comprises a light chain variable region comprising amino acid residues 23 to 128 of SEQ ID NO: 4, a human immunoglobulin light chain kappa constant region, a heavy chain variable region comprising amino acid residues 20 to 140 of SEQ ID NO: 6, and a human immunoglobulin heavy chain gamma 1 constant region.